Johnson & Johnson (NYSE:JNJ – Get Free Report) released its quarterly earnings results on Wednesday. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11, RTT News reports. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.79%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.80 earnings per share. Johnson & Johnson updated its FY24 guidance to $9.97-10.07 EPS and its FY 2024 guidance to 9.970-10.070 EPS.
Johnson & Johnson Stock Performance
Shares of Johnson & Johnson stock opened at $155.44 on Friday. The firm has a fifty day moving average of $148.26 and a two-hundred day moving average of $153.40. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The stock has a market capitalization of $374.09 billion, a price-to-earnings ratio of 9.69, a PEG ratio of 2.76 and a beta of 0.52. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Further Reading
- Five stocks we like better than Johnson & Johnson
- Investing In Automotive Stocks
- Why These 4 AI Stocks Are Must-Watch for 2024 Investors
- Health Care Stocks Explained: Why You Might Want to Invest
- Pharma Leader Beats on Earnings, But Shares Fall
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Oracle Pulls Back After Musk Deal Falls Through, Time to Buy?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.